Skip to main content

Wall Street Analysts Are Bullish on Top Healthcare Picks

Tipranks - Thu Feb 19, 8:04PM CST

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Community Health (CYHResearch Report) and Perspective Therapeutics (CATXResearch Report) with bullish sentiments.

President's Day Sale - 70% Off

Community Health (CYH)

RBC Capital analyst Ben Hendrix maintained a Buy rating on Community Health on February 17 and set a price target of $5.00. The company’s shares closed last Wednesday at $3.34.

According to TipRanks.com, Hendrix is a 4-star analyst with an average return of 5.2% and a 51.9% success rate. Hendrix covers the Healthcare sector, focusing on stocks such as Concentra Group Holdings Parent, Inc., Ardent Health Partners, Inc., and Aveanna Healthcare Holdings. ;'>

Community Health has an analyst consensus of Hold, with a price target consensus of $3.67, representing an 8.3% upside. In a report issued on February 3, TipRanks – Google also upgraded the stock to Buy with a $3.50 price target.

See the top stocks recommended by analysts >>

Perspective Therapeutics (CATX)

In a report issued on February 17, Leonid Timashev from RBC Capital maintained a Buy rating on Perspective Therapeutics, with a price target of $18.00. The company’s shares closed last Wednesday at $5.03.

According to TipRanks.com, Timashev is a 5-star analyst with an average return of 19.0% and a 56.4% success rate. Timashev covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Jazz Pharmaceuticals, and Revolution Medicines. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Perspective Therapeutics with a $12.50 average price target, a 158.8% upside from current levels. In a report issued on February 12, JonesTrading also maintained a Buy rating on the stock with a $18.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.